益气温阳活血利水方对CRS患者炎性反应的影响

益气温阳活血利水方对CRS患者炎性反应的影响

冯伟,张晶,方芳

河北省唐山市中医医院,河北省唐山市中医医院,河北省唐山市中医医院心内一科

收稿日期:2017-08-14 修回日期:2017-09-01 出版日期:2017-11-25
基金资助:
河北省中医药管理局科研计划项目(项目编号：2014248；项目名称：益气温阳活血利水法干预心肾综合征患者心肾功能的临床研究)

Effect of Yiqi Wenyang Huoxue Lishui Decoction on Inflammatory Reaction in CRS Patients

FENGwei,ZHANGjing and FANGfang

Tangshan Hospital of traditional Chinese medicine Cardiology NO.1,Tangshan Hospital of traditional Chinese medicine Cardiology NO.1,Tangshan Hospital of traditional Chinese medicine Cardiology NO.1,Hebei Tangshan

Received:2017-08-14 Revised:2017-09-01 Online:2017-11-25

摘要/Abstract

摘要： 目的：探讨炎性反应与心肾综合征（CRS）发病的相关性，观察益气温阳活血利水方对CRS患者炎性反应的影响。方法：选取2014年1月至2015年7月入住我院心内科、肾内科及ICU的患者共243例，最终纳入研究232例，根据心肾功能水平将入选患者分为对照组（A组59例），单纯心衰组（B组61例），单纯肾衰组（C组62例），CRS（D组61例）。对各组受试者入院24h及应用益气温阳活血利水方满疗程后空腹抽取静脉血，分别测定患者治疗前后白介素-6（IL-6）、细胞间粘附因子-1（sICAM-1）、肿瘤坏死因子α（TNF-α）、血清淀粉样蛋白A(SAA)水平，均采用分光比色法。对照组、单纯心衰组及单纯肾衰组采用西医对症治疗，CRS组在西医治疗基础上加用益气温阳活血利水方治疗，4组疗程均为20d，疗程结束后对比4组患者炎性反应改善情况。结果：B组、C组、D组治疗前IL-6、sICAM-1、TNF-α、SAA水平均高于A组，D组治疗前IL-6、sICAM-1、TNF-α、SAA水平均高于A组、B组及C组，差异有统计学意义（P<0.05）。B组、C组、D组治疗后IL-6、sICAM-1、TNF-α、SAA水平均有所降低，D组治疗后IL-6、sICAM-1、TNF-α、SAA水平降低幅度均大于B组、C组，差异均有统计学意义（P<0.05）；A组治疗前后IL-6、sICAM-1、TNF-α、SAA水平比较无明显改变，差异均无统计学意义（P<0.05）。结论：炎性反应与CRS发病密切相关，益气温阳活血利水方能够改善CRS患者炎性反应。

Abstract: [Objective： To investigate the relationship between inflammatory reaction and Cardiorenal Syndrome(CRS) disease， observe the function of Yiqi Wenyang Huoxue Lishui Decoction on inflammatory reaction in patients with CRS. Methods： Select a total of 243 patients in cardiology department， urology department and ICU of our hospital from January 2014 to July 2015， and eventually 232 cases into the study，according to the heart and kidney function divided the patients into control group(group A 59 cases)， pure heart failure group(group B 61 cases)， simple renal failure group(group C 62 cases)， CRS group(group D 61 cases). To each group subjects， fasting venous blood were drawn when admitted to hospital 24 h and application of Yiqi Wenyang Huoxue Lishui Decoction the full course， determined before and after treatment the patients′ interleukin 6(IL 6)，intercellular adhesion factor 1(sICAM 1)， tumor necrosis factor alpha(TNF alpha)， serum amyloid A(SAA)， adopt spectral colorimetric method. The control group， the pure heart failure group and simple renal failure group using western medicine symptomatic treatment， CRS group on the basis of western medicine treatment for Yiqi Wenyang Huoxue Lishui Decoction treatment， all four groups of treatment for 20d， after the treatment four groups of patients with inflammatory reaction were compared. Results： Before treatment IL-6， sICAM-1， TNF alpha， SAA level in group B， group C and group D were higher than in group A； before treatment IL-6， sICAM-1， TNF alpha， SAA levels in Group D were higher than in group A， group B and group C， with statistical difference(P<0.05). IL-6， sICAM-1， TNF alpha， SAA levels in group B， group C， group D were reduced； after treatment IL-6， sICAM-1， TNF alpha， SAA levels in group D were greater than group B， group C， statistically difference(P<0.05)； Before and after treatment in group A IL-6， sICAM-1， TNF alpha， SAA level had no obvious change， had no statistical difference(P<0.05). Conclusion： The inflammatory reaction is closely associated with the onset of CRS， Yiqi Wenyang Huoxue Lishui Decoction can improve inflammatory reaction in CRS patients.

冯伟,张晶,方芳. 益气温阳活血利水方对CRS患者炎性反应的影响[J]. .

FENGwei,ZHANGjing and FANGfang. Effect of Yiqi Wenyang Huoxue Lishui Decoction on Inflammatory Reaction in CRS Patients[J]. .

参考文献

[1]RONCO C, MCCULLOUGH P, ANKER S D, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative[J]. Eur Heart J, 2010,31:703-711.
[2]RONCO C,HOUSE A A,HAAPIO M.Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong[J].Intensive Cara Med, 2008, 34,957-962.
[3]陈再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008: 170,549.
[4]Metra M,Nodari S,Parrinello G,et al.Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance[J].Eur J Heart Fail,2008,10(2):188-195.
[5]Ronco C,McCullough P,Anker SD,et al.Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative[J].Eur Heart J,2010,31(6):703-711.
[6]RONCO C,MCCULLOUGH P,ANKER SD,et al.Cardio-renalSyndromes: report from the consensus conference of the acute dialysis quality initiative[J].Eur Heart J,2010,31(6):703－711．
[7]Collins AJ, Foley RN, Chavers B, et al．United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease ＆ end-stage renal disease in the United States[J].Am J Kidney Dis,2012,59(1 Suppl 1):A7,e1－e420.
[8]Amann K,Tyralla K.Cardiovascular changes in chronic renal failure －－pathogenesis and therapy[J].Clin Nephrol,2002,58(Suppl 1):S62-S72.
[9]韩越.真武汤对心肾综合征大鼠的心肾保护作用[J].实用医学杂志,2015,31(13):2112-2114.
[10]欧阳秋芳,游涛.心肾综合征中医研究近况[J].医学综述,2011,3(17):772-773.
[11]邹艳玲.中西医结合治疗心肾综合征临床研究[J]. 中医学报,2014,4(4):480-581.
[12]Levine B,Kalman J,Mayer L,et al.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J].N Engl J Med,1990,3(23):236–241.
[13]Torre-Amione G.Immune activation in chronic heart failure[J].Am J Cardiol,2005(95):3C–8C.
[14]Mantovani A,Garlanda C,Bottazzi BP,et al.The long pentraxin PTX3 in vascular pathology[J].Vascul Pharmacol,2006(45):326–330.
[15]Frantz S, Ertl G, Bauersachs J.Mechanisms of disease:toll-like receptors in cardiovascular disease[J].Nat ClinPract Cardiovasc Med,2007(4):444–454.
[16]Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches[J].Am J Cardiol, 2005(95):17C–23C.discussion 38C–40C.
[17]Mann DL, Mc Murray JJ, Packer M,et al.Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) [J].Circulation,2004(109):1594–1602.
[18]Anker SD,Coats AJ.How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH[J].Int J Cardiol,2002(86):123–130.
[19]Heyman S,Hirsch E,Anker SD,et al.Inflammatio as a therapeutic target in heart failure?A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology[J].Eur J Heart Fail,2009(11):119–129.
[20]Rauchhaus M,Doehner W,Francis DP,et al.Plasma cytokineparameters and mortality in patients with chronic heart failure.Circulation,2000(102):3060–3067.
[21]Mutlu GM,Sznajder JI.Mechanisms of pulmonary edema clearance[J].Am J Physiol Lung Cell Mol Physiol 2005(289):L685–L689.
[22]Cotter G, Metra M, Milo-Cotter O, et al.Fluid overload in acute heart failure: re-distribution and other mechanisms beyond fluid accumulation[J].Eur J Heart Fail,2008(10):165–169.
[23]Khan SR. Stress oxidative: nephrolithiasis and chronic kidney diseases[J]. Minerva Med, 2013, 104(1): 23-30.
[24]Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation:Toll-like receptors[J]. Free Radic Biol Med, 2010, 48(9): 1121-1132.
[25]周胜元.从中西医结合角度探讨心肾综合征的发病机制与治疗[J].西部中医药,2013,26(1)：121-124.
[26]程锦.从升降、表里、阴阳探讨心肾关系[J].陕西中医学院学报,2008,11(31)：17-18.
[27]王韶兵.益气温阳活血利水方治疗慢性心力衰竭的临床观察[J].中国临床研究,2011,3(22)：53-54.

快速检索引用检索图表检索高级检索